Literature DB >> 10100697

Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.

P Salven1, A Orpana, H Joensuu.   

Abstract

Vascular endothelial growth factor (VEGF) is a secreted endothelial cell-specific mitogen and permeability factor. Malignant human tumors have been shown to produce VEGF. Elevated levels of VEGF have been detected in sera of cancer patients, but its origin is unsettled. We analyzed VEGF concentrations in serum, plasma, whole blood, and peripheral blood mononuclear cells (PBMNCs) and platelets in 56 cancer patients and 52 healthy controls using ELISA. The VEGF concentrations in the lysed whole blood samples [blood VEGF (B-VEGF)] were higher in cancer patients than in healthy controls (median, 464 versus 298 pg/ml; P<0.0001). The highest B-VEGF values were found in disseminated cancer. In cancer patients, a high B-VEGF concentration was associated with a high peripheral blood leukocyte count (P = 0.0012) and platelet count (P = 0.019). In healthy individuals, a high B-VEGF was associated with a high leukocyte count (P = 0.0001) but not with the platelet count (P>0.1). The cancer patients regularly had higher B-VEGF concentrations than healthy individuals with comparable leukocyte or platelet counts. The VEGF content of isolated PBMNCs and platelets was severalfold higher in cancer patients than in healthy controls (median, 10.6 versus 0.9 pg per 10(6) PBMNCs, and median, 1.6 versus 0.5 pg per 10(6) platelets; P<0.0001 and P = 0.0008, respectively). Serum VEGF and B-VEGF correlated strongly (P<0.0001). Very little or no VEGF was found in the plasma. The results indicate that VEGF in the bloodstream is transported by blood cells, including leukocytes and platelets. The blood cells of cancer patients contain greatly elevated amounts of this major angiogenic growth factor, and this reservoir of VEGF may have a role in tumor angiogenesis and metastasis formation. VEGF in serum samples originates from blood cells, and the use of VEGF of whole blood or of isolated blood cells may improve the clinical value of VEGF measurements.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100697

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model.

Authors:  Bethany A Kerr; Ranko Miocinovic; Armine K Smith; Eric A Klein; Tatiana V Byzova
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

Review 2.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

3.  Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods.

Authors:  Avraham Belizon; Emre Balik; Daniel L Feingold; Marc Bessler; Tracey D Arnell; Kenneth A Forde; Patrick K Horst; Suvinit Jain; Vesna Cekic; Irena Kirman; Richard L Whelan
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

4.  Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma.

Authors:  Munechika Enjoji; Makoto Nakamuta; Koji Yamaguchi; Satoshi Ohta; Kazuhiro Kotoh; Marie Fukushima; Masami Kuniyoshi; Tomomi Yamada; Masao Tanaka; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

5.  Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series.

Authors:  Sabine Brookman-May; Matthias May; Vincenzo Ficarra; Manuela Christine Kainz; Karin Kampel-Kettner; Stephanie Kohlschreiber; Valentina Wenzl; Meike Schneider; Maximilian Burger; Wolf F Wieland; Wolfgang Otto; Derya Tilki; Christian Gilfrich; Markus Hohenfellner; Sascha Pahernik; Thomas F Chromecki; Christian Stief; Richard Zigeuner
Journal:  World J Urol       Date:  2012-08-19       Impact factor: 4.226

Review 6.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

7.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

8.  [Markers in patients with squamous cell carcinoma of the oral cavity. Expression and long-term follow-up of VEGF, FLT-1 and Tie2 in serum].

Authors:  R Schimming; N-C Gellrich; G Eyrich
Journal:  HNO       Date:  2004-03       Impact factor: 1.284

9.  The prognostic significance of the preoperative full blood count after resection of colorectal liver metastases.

Authors:  K Dajani; D A O'Reilly; N De Liguori Carino; P Ghaneh; G Poston; A Wu
Journal:  HPB Surg       Date:  2009-09-08

10.  Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia.

Authors:  S Molica; G Vitelli; D Levato; A Ricciotti; G Digiesi
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.